Some patients in the UK with chronic kidney disease (CKD) who develop chronic itching – one of the most common and challenging side effects of dialysis – will soon be able
Vifor Pharma and Cara Therapeutics' Kapruvia has become the first drug to be approved in the EU to treat one of the most common and challenging side effects for people undergoing dialysis f
One of the most common and challenging side effects for people undergoing dialysis for chronic kidney disease – chronic itching – now has an FDA-approved treatment.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh